Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia

Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia

Abstract Venetoclax (VEN) plus azacitidine has become the first-line therapy for elderly patients with acute myeloid leukemia (AML), and has a complete remission (CR) plus CR with incomplete recovery of hemogram rate of ≥70%. However, the 3-year survival rate of these patients is < 40% due to rel...

Full description

Bibliographic Details
Main Authors: Xiang Zhang, Jiejing Qian, Huafeng Wang, Yungui Wang, Yi Zhang, Pengxu Qian, Yinjun Lou, Jie Jin, Honghu Zhu
Format: Article
Language:English
Published: BMC 2021-05-01
Series:Biomarker Research
Subjects:
Venetoclax
Acquired resistance
Acute myeloid leukemia
Online Access:https://doi.org/10.1186/s40364-021-00288-7

Internet

https://doi.org/10.1186/s40364-021-00288-7

Similar Items